CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF655 (ImmuneEditome ID:79027)

1. Gene summary of enriched editing regions for ZNF655

check button Gene summary
Gene informationGene symbol

ZNF655

Gene ID

79027

GeneSynonymsVIK|VIK-1
GeneCytomap

7q22.1

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 655|vav-1 interacting Kruppel-like protein
GeneModificationdate20230518
UniprotIDC9J0V9;Q8N720;F8WDU5;C9JUB9;C9JNK1;C9J9R2;F8WEB1;F8WE52;C9JS03;F8WCS2;C9IYG2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr7:99566560-99569054:+ENST00000493947.4ENSG00000197343.9ZNF655ncRNA_intronicAluJb,AluJo,AluSz6,AluSg,AluSc8,MIRb,(TTGA)n,AluSpchr7:99566560-99569054:+.alignment
chr7:99574454-99575492:+ENST00000419215.2ENSG00000197343.9ZNF655ncRNA_exonicAluJr,AluSgchr7:99574454-99575492:+.alignment
chr7:99574454-99575492:+ENST00000494357.1ENSG00000197343.9ZNF655ncRNA_exonicAluJr,AluSgchr7:99574454-99575492:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF655


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr7:99574454-99575492:+BRCAEER5.3830e-14image
ENSG00000197343.9,ZNF655BRCAEAG8.9235e-03image
ENSG00000197343.9,ZNF655COADEAG2.9318e-04image
ENSG00000197343.9,ZNF655KICHEAG1.0227e-02image
ENSG00000197343.9,ZNF655KIRCEAG8.8999e-03image
ENSG00000197343.9,ZNF655KIRPEAG2.0583e-02image
ENSG00000197343.9,ZNF655LUADEAG2.4843e-08image
ENSG00000197343.9,ZNF655LUSCEAG1.5864e-02image
ENSG00000197343.9,ZNF655PRADEAG1.3591e-10image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr7:99566560-99569054:+HNSCPathEER1.9722e-031.3231e-030.4376image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF655


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr7:99566560-99569054:+LAMLEERENSG00000116221,MRPL370.36163.9920e-021.3360e-070.4490imageNAUH;BCCIP;CSTF2T;DKC1;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;IGF2BP2;NOP56;PCBP2;RBFOX2;TAF15;TIA1NAMast_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2

More results



Top

4. Enriched editing regions and immune related splicing for ZNF655


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr7:99574454-99575492:+
ESCAEERIRENSG00000175711.4chr1782942464:82942682:82943821:82944049-0.33912.0219e-029.7970e-06-0.4544imageNNB3GNTL1GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000165689.12chr9136404630:136404693:136405090:1364052020.36028.8080e-031.5676e-070.4150imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000131067.12chr2034854795:34854923:34856805:348568930.34391.6577e-026.7679e-090.4541imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAGNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000183891.5chr219896642:19897126:19897868:198980260.31663.1744e-024.2111e-070.4055imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_PEROXISOME
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000134686.12chr133325824:33327427:33328869:333291460.34792.2118e-031.9594e-090.5156imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_ADIPOGENESIS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000130827.5chrX154464156:154464868:154465017:1544652180.30081.6624e-027.0344e-060.4036imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PLXNA3Dendritic_cells_activatedGSVA_HALLMARK_ADIPOGENESIS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000165915.9chr1147411925:47412039:47412345:474124670.31903.2624e-024.8116e-070.4023imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000068137.10chr1742670572:42670705:42671002:426711300.32488.9585e-033.3585e-070.4391imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RC3H1;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000169733.7chr1782049676:82050764:82051293:820513350.34391.6701e-021.2598e-070.4179imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
ENSG00000197343.9,ZNF655
GBMEAGIRENSG00000131459.8chr5180330699:180330834:180331494:1803315530.30633.2659e-026.8560e-070.4135imageNACIN1;ADAR;AIFM1;CNBP;CSTF2T;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA2B1;HNRNPC;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28A;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;TAF15;TARBP2;TARDBP;TIA1;TIAL1;U2AF2;UPF1;YTHDC1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for ZNF655


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000197343.9,ZNF655ACCEAGNK_cells_resting3.6638e-030.4544image
ENSG00000197343.9,ZNF655BLCAEAGDendritic_cells_activated7.5008e-05-0.2710image
chr7:99566560-99569054:+BRCAEERT_cells_CD4_memory_activated9.3947e-030.1409image
chr7:99574454-99575492:+BRCAEERT_cells_CD4_memory_activated3.1183e-070.1720image
ENSG00000197343.9,ZNF655BRCAEAGT_cells_CD4_memory_activated8.2238e-060.1485image
chr7:99566560-99569054:+CESCEERDendritic_cells_resting5.7189e-030.4705image
ENSG00000197343.9,ZNF655CESCEAGNK_cells_activated3.3345e-030.2159image
ENSG00000197343.9,ZNF655CHOLEAGNK_cells_activated4.5990e-040.6178image
chr7:99566560-99569054:+COADEERB_cells_memory3.2744e-02-0.4564image
ENSG00000197343.9,ZNF655COADEAGDendritic_cells_activated2.2847e-040.3344image
chr7:99566560-99569054:+ESCAEERT_cells_CD4_naive1.6281e-020.2600image
chr7:99566560-99569054:+GBMEERNeutrophils2.5927e-020.3934image
ENSG00000197343.9,ZNF655GBMEAGT_cells_gamma_delta3.5400e-02-0.1731image
chr7:99566560-99569054:+HNSCEERPlasma_cells1.6737e-030.4037image
ENSG00000197343.9,ZNF655HNSCEAGMacrophages_M21.3821e-020.1319image
chr7:99566560-99569054:+KICHEERMast_cells_activated4.8408e-040.6159image
chr7:99566560-99569054:+KIRCEERPlasma_cells6.3052e-040.2815image
chr7:99574454-99575492:+KIRCEERPlasma_cells3.4993e-030.1550image
ENSG00000197343.9,ZNF655KIRCEAGPlasma_cells2.8837e-020.1157image
chr7:99566560-99569054:+KIRPEERMacrophages_M01.5467e-020.2416image
ENSG00000197343.9,ZNF655KIRPEAGT_cells_CD84.7627e-02-0.1362image
chr7:99566560-99569054:+LGGEERT_cells_CD86.5010e-030.1851image
ENSG00000197343.9,ZNF655LGGEAGT_cells_follicular_helper1.3857e-020.1178image
ENSG00000197343.9,ZNF655LIHCEAGEosinophils3.7410e-020.1679image
ENSG00000197343.9,ZNF655LUADEAGMacrophages_M16.1527e-050.1909image
chr7:99566560-99569054:+LUSCEERT_cells_CD4_memory_activated1.8196e-020.1933image
ENSG00000197343.9,ZNF655LUSCEAGT_cells_CD4_memory_resting1.6844e-02-0.1190image
ENSG00000197343.9,ZNF655MESOEAGT_cells_CD4_naive2.3953e-090.6439image
chr7:99566560-99569054:+OVEERT_cells_gamma_delta8.4794e-090.8860image
ENSG00000197343.9,ZNF655OVEAGT_cells_CD4_naive3.0258e-100.4024image
chr7:99566560-99569054:+PAADEEREosinophils2.5835e-040.5472image
ENSG00000197343.9,ZNF655PAADEAGT_cells_follicular_helper2.4073e-030.2510image
ENSG00000197343.9,ZNF655PCPGEAGB_cells_memory9.9445e-040.2772image
ENSG00000197343.9,ZNF655PRADEAGDendritic_cells_activated1.7780e-030.2129image
ENSG00000197343.9,ZNF655READEAGMacrophages_M25.3040e-040.5233image
ENSG00000197343.9,ZNF655SARCEAGT_cells_CD82.7472e-050.3130image
ENSG00000197343.9,ZNF655SKCMEAGDendritic_cells_activated1.7641e-02-0.1242image
chr7:99574454-99575492:+STADEERMast_cells_activated3.7790e-03-0.1815image
ENSG00000197343.9,ZNF655STADEAGB_cells_memory1.4049e-030.1931image
chr7:99566560-99569054:+TGCTEERT_cells_CD4_memory_resting3.5961e-03-0.5316image
ENSG00000197343.9,ZNF655TGCTEAGPlasma_cells2.7791e-030.2777image
chr7:99566560-99569054:+THCAEERT_cells_CD4_memory_activated4.5530e-020.2138image
chr7:99566560-99569054:+THYMEERT_cells_gamma_delta4.9867e-030.5764image
ENSG00000197343.9,ZNF655THYMEAGB_cells_naive9.5181e-030.3036image
ENSG00000197343.9,ZNF655UCECEAGMacrophages_M22.9104e-020.2628image


Top

6. Enriched editing regions and immune gene sets for ZNF655


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000197343.9,ZNF655BLCAGSVA_HALLMARK_E2F_TARGETSEAG1.1930e-020.1740image
chr7:99566560-99569054:+BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.8921e-020.3161image
ENSG00000197343.9,ZNF655BRCAGSVA_HALLMARK_MYOGENESISEAG9.9783e-09-0.1902image
chr7:99574454-99575492:+BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER6.6327e-200.3021image
chr7:99566560-99569054:+CESCGSVA_HALLMARK_MYC_TARGETS_V2EER4.4411e-020.3522image
ENSG00000197343.9,ZNF655CESCGSVA_HALLMARK_HEME_METABOLISMEAG1.3207e-02-0.1829image
ENSG00000197343.9,ZNF655CHOLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.0565e-02-0.4354image
ENSG00000197343.9,ZNF655COADGSVA_HALLMARK_SPERMATOGENESISEAG2.7133e-05-0.3775image
ENSG00000197343.9,ZNF655ESCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.5186e-03-0.2775image
chr7:99574454-99575492:+ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER8.4339e-03-0.2385image
chr7:99566560-99569054:+ESCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.3826e-020.2305image
ENSG00000197343.9,ZNF655GBMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.1086e-04-0.3124image
chr7:99566560-99569054:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.8934e-020.3668image
ENSG00000197343.9,ZNF655HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.6199e-030.1386image
chr7:99574454-99575492:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.9000e-050.2085image
chr7:99566560-99569054:+KIRCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.9801e-020.1940image
ENSG00000197343.9,ZNF655KIRCGSVA_HALLMARK_MYC_TARGETS_V1EAG1.4329e-04-0.1999image
ENSG00000197343.9,ZNF655KIRPGSVA_HALLMARK_UV_RESPONSE_UPEAG2.9869e-04-0.2460image
chr7:99566560-99569054:+LAMLGSVA_HALLMARK_MYC_TARGETS_V2EER1.7551e-020.2113image
ENSG00000197343.9,ZNF655LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1607e-02-0.2135image
ENSG00000197343.9,ZNF655LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.6032e-09-0.2838image
ENSG00000197343.9,ZNF655LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.2958e-040.2803image
ENSG00000197343.9,ZNF655LUADGSVA_HALLMARK_G2M_CHECKPOINTEAG5.1697e-050.1928image
chr7:99566560-99569054:+LUSCGSVA_HALLMARK_NOTCH_SIGNALINGEER2.4675e-020.1840image
ENSG00000197343.9,ZNF655LUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.6813e-02-0.1103image
ENSG00000197343.9,ZNF655MESOGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.5997e-03-0.3373image
ENSG00000197343.9,ZNF655OVGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG2.8976e-02-0.1450image
ENSG00000197343.9,ZNF655PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.3952e-03-0.2511image
ENSG00000197343.9,ZNF655PCPGGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.4802e-040.3071image
chr7:99566560-99569054:+PRADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.8892e-020.4073image
ENSG00000197343.9,ZNF655SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.4424e-040.2642image
ENSG00000197343.9,ZNF655SKCMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG5.3421e-050.2098image
chr7:99574454-99575492:+STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.2241e-020.1278image
ENSG00000197343.9,ZNF655STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.6918e-05-0.2446image
ENSG00000197343.9,ZNF655TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG5.3932e-03-0.2590image
chr7:99566560-99569054:+THCAGSVA_HALLMARK_MYOGENESISEER3.3987e-02-0.2263image
ENSG00000197343.9,ZNF655THCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG8.9377e-06-0.2286image
ENSG00000197343.9,ZNF655THYMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG5.1003e-04-0.3994image
ENSG00000197343.9,ZNF655UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG8.2415e-03-0.3156image
ENSG00000197343.9,ZNF655UCSGSVA_HALLMARK_UV_RESPONSE_UPEAG1.1350e-020.4487image


Top

7. Enriched editing regions and drugs for ZNF655


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000197343.9,ZNF655ACCMethotrexateEAG4.3760e-04-0.5359image
ENSG00000197343.9,ZNF655BLCACCT007093EAG1.0678e-030.2253image
chr7:99566560-99569054:+BRCAAxitinibEER4.0564e-020.1113image
ENSG00000197343.9,ZNF655BRCAJNK.Inhibitor.VIIIEAG1.4055e-05-0.1448image
chr7:99574454-99575492:+BRCACCT007093EER4.7777e-100.2086image
ENSG00000197343.9,ZNF655CESCA.770041EAG2.8881e-03-0.2191image
chr7:99566560-99569054:+CESCKIN001.135EER6.0874e-030.4675image
ENSG00000197343.9,ZNF655CHOLAG.014699EAG1.6950e-02-0.4475image
chr7:99566560-99569054:+COADAZD7762EER8.4584e-03-0.5468image
ENSG00000197343.9,ZNF655COADAZ628EAG8.9158e-040.3032image
ENSG00000197343.9,ZNF655DLBCCHIR.99021EAG1.7456e-02-0.5250image
ENSG00000197343.9,ZNF655ESCAJW.7.52.1EAG1.4934e-030.2779image
chr7:99574454-99575492:+ESCACamptothecinEER1.5534e-02-0.2196image
chr7:99566560-99569054:+ESCAElesclomolEER3.5323e-02-0.2286image
ENSG00000197343.9,ZNF655GBMDocetaxelEAG2.2300e-030.2495image
chr7:99566560-99569054:+HNSCLenalidomideEER5.9841e-03-0.3567image
ENSG00000197343.9,ZNF655HNSCGefitinibEAG2.4257e-02-0.1211image
chr7:99566560-99569054:+KICHCamptothecinEER9.8605e-03-0.4793image
ENSG00000197343.9,ZNF655KICHJNJ.26854165EAG3.1380e-020.3213image
chr7:99566560-99569054:+KIRCKIN001.135EER3.3804e-02-0.1770image
ENSG00000197343.9,ZNF655KIRCLenalidomideEAG9.4224e-06-0.2327image
chr7:99574454-99575492:+KIRCCisplatinEER4.4695e-06-0.2414image
chr7:99566560-99569054:+KIRPGW.441756EER8.2759e-03-0.2627image
ENSG00000197343.9,ZNF655KIRPDocetaxelEAG9.7564e-050.2644image
chr7:99566560-99569054:+LAMLA.443654EER3.9109e-04-0.3111image
ENSG00000197343.9,ZNF655LAMLBI.2536EAG5.7731e-03-0.2330image
chr7:99566560-99569054:+LGGEHT.1864EER4.7328e-02-0.1354image
ENSG00000197343.9,ZNF655LGGErlotinibEAG3.3597e-050.1975image
ENSG00000197343.9,ZNF655LIHCAUY922EAG2.9004e-030.2384image
chr7:99566560-99569054:+LUADAZ628EER4.8471e-02-0.1572image
ENSG00000197343.9,ZNF655LUADAKT.inhibitor.VIIIEAG1.1869e-06-0.2304image
chr7:99566560-99569054:+LUSCGDC.0449EER1.1758e-02-0.2059image
ENSG00000197343.9,ZNF655LUSCBIBW2992EAG1.1358e-02-0.1260image
chr7:99566560-99569054:+OVKU.55933EER7.3175e-030.5330image
ENSG00000197343.9,ZNF655PAADBMS.754807EAG2.7044e-020.1876image
chr7:99566560-99569054:+PAADDMOGEER3.1849e-020.3400image
ENSG00000197343.9,ZNF655PCPGEpothilone.BEAG9.0422e-050.3270image
ENSG00000197343.9,ZNF655PRADCCT018159EAG9.5168e-030.1773image
ENSG00000197343.9,ZNF655READAZD6244EAG3.2638e-02-0.3428image
ENSG00000197343.9,ZNF655SARCBMS.754807EAG5.0033e-050.3032image
chr7:99566560-99569054:+SKCMGW.441756EER4.0874e-02-0.1894image
ENSG00000197343.9,ZNF655SKCMGNF.2EAG1.4871e-05-0.2245image
ENSG00000197343.9,ZNF655STADATRAEAG2.8050e-03-0.1812image
chr7:99566560-99569054:+STADCisplatinEER2.1732e-020.1939image
ENSG00000197343.9,ZNF655TGCTAZD8055EAG1.8647e-02-0.2200image
chr7:99566560-99569054:+TGCTCEP.701EER4.1187e-02-0.3882image
chr7:99566560-99569054:+THCABortezomibEER1.9560e-020.2485image
ENSG00000197343.9,ZNF655THCABIRB.0796EAG4.6189e-04-0.1812image
chr7:99566560-99569054:+THYMGSK.650394EER2.8545e-03-0.6050image
ENSG00000197343.9,ZNF655THYMABT.263EAG1.3431e-040.4350image
ENSG00000197343.9,ZNF655UCECDoxorubicinEAG6.2248e-030.3262image
ENSG00000197343.9,ZNF655UCSJW.7.52.1EAG9.9647e-03-0.4558image
ENSG00000197343.9,ZNF655UVMCCT018159EAG3.1792e-02-0.4486image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType